

First-in-Class HER2 Immunotherapy

Inducing durable control
in HER2-driven cancers

ØU – Life Science Investor Conference
25 March 2026
Bent U. Frandsen, CEO

STO: EXPRS2




ExpreS2ion Biotech Holding AB
Org. Nr. 559033-3729



Hosted by
**Konferencer
& Seminarer**

Expres2ion at a Glance

Clinical-stage biotech developing immunotherapies and vaccines

 Lead Asset	 Platform	 Strategic Position
ES2B-C001 HER2 immunotherapy	Expres2™ protein manufacturing technology	34% AdaptVac ownership
Phase I clinical	Phase III validated	Broad infectious diseases pipeline
		CRO services business

Quick facts

- Founded 2010
- Nasdaq First North Growth Market Stockholm since 2016
- 18 FTEs in DTU Science Park Hørsholm, Denmark

The Unmet Need

Breast Cancer: The #1 Killer in Women's Health – key background for lead asset

Problem

- 2.3 million women diagnosed each year¹ – the most common cancer
- 685,000 annual deaths² – the leading cause of cancer mortality

Limitation of current therapies

- Resistance develops
- Limited durability
- Safety aspects

Opportunity for immunotherapy



- Durable immune control

Durable immune control remains the missing piece in HER2-driven cancer

¹ WHO/IARC. GLOBOCAN 2020: Breast Cancer Fact Sheet. Global Cancer Observatory, Lyon, France. Available at: <https://gco.iarc.fr/>
² Kim J, Harper A, McCormack V, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31:1154–1162.
³ Wolff AC, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2018;36:2105–2122.
⁴ Escrivá-de-Romani S, et al. "Resistance to HER2-targeted therapies in breast cancer." Cancer Treat Rev. 2018; 71:28–41.

Our Technology Platform

Expres2™ is applied in ALL our business – VLP technology exclusively in-licensed for lead asset ES2B-C001

<ul style="list-style-type: none"> • Capabilities <ul style="list-style-type: none"> • >500 proteins expressed • 90% success rate • Used in biologics, diagnostics and vaccines • Basis for all our pipeline activities • Clinical validation <ul style="list-style-type: none"> • Used in more than a dozen human studies • Platform met primary endpoint in a Phase III study with >4,000 participants 	<div style="display: flex; justify-content: space-around;"> <div style="text-align: center;"> <div style="background-color: #003366; color: white; padding: 5px; border-radius: 10px; width: 150px; margin: 0 auto;">Expres2 platform</div>  <p style="font-size: small;">Cell line derived from <i>Drosophila melanogaster</i> (fruit fly) S2 cells¹</p> </div> <div style="text-align: center;"> <div style="background-color: #003366; color: white; padding: 5px; border-radius: 10px; width: 150px; margin: 0 auto;">AdaptVac VLP technology</div> <p style="font-size: small; color: #003366;">Exclusive license for HER2-VLP</p>  </div> </div>	<ul style="list-style-type: none"> • Capabilities <ul style="list-style-type: none"> • High antigen density • Strong immune activation • Clinical Ph. III validated • Commercial validation <ul style="list-style-type: none"> • Concept used in approved HPV vaccines
--	---	--

COVID-19 picture: Expres2 protein (antigen) combined with AdaptVac's VLP containing no viral genetic material causing an immune reaction

Expres2 protein + VLP display = Strong durable immune response

¹Schneider I (1972). "Cell Lines Derived from Late Embryonic Stages of *Drosophila melanogaster*". *J. Embryol. Exp. Morphol.* 27: 363–365.
Note: Expres2ion Biotech founders invented an Improved Vector System derived from S2 cells; granted patent until 2032 (US); glyco-engineered S2 cells pending patents until 2040.

ES2B-C001: First-in-Class HER2 Immunotherapy


Active immunotherapy designed to induce durable immune control

- Mechanism
 - Presents entire HER2 extracellular domain
 - Generates polyclonal immune response
 - Targets multiple HER2 epitopes

- Comparison

Current HER2 therapies	ES2B-C001
🎯 single epitope	🧬 multi-epitope response
💉 repeated dosing	🛡️ immune memory
⚠️ resistance	🔄 durable control

- Positioning:



Designed to complement existing HER2 therapies


Note: Multilayered patent protection in accordance with patent strategy. Patent priority application filed in May 2025 ("Virus-Like Particles displaying HER-2 extracellular domain") – expected validity through 2046, without extensions.

mAb = monoclonal antibody treatments
SoC = standard of care
HPV = human papilloma virus

VLP = virus-like particle
HER2 = human epidermal growth factor receptor 2

ES2B-C001: Preclinical Proof-of-Concept

Significant *in vivo* tumour inhibition resulted in 100% survival rate in FVB mice



- **Metastasis prevention**
Vaccinated animals remained tumour-free while controls developed metastases
- **Durable effect**
Prevented spread in animals

Strong preclinical support for immune-mediated tumour control


ES2B-C001: Phase I Clinical Trial

Preliminary findings support the program

Trial design

- **Population:** ≤27 advanced HER2-positive or HER2-low breast cancer patients (post 2-3 lines SoC therapy) ¹
- **Sites:** Three clinical centres in Austria
- **Treatment:** Intramuscular vaccine, five doses across three dose levels; optional combination with standard ADC
- **Objectives:** Primary - safety; Secondary - immunogenicity
- **Timeline:** Phase Ia data mid-2026; Phase Ib data end-2026
- **Outcome:** Safety and tolerability at biologically active dose; recommended Phase II dose

Early observations



Geometric mean titers calculated from all patients with evaluable samples at each visit (n=10 at early visits, declining with ongoing follow-up). Exploratory Phase 1 data ²

- ✓ **No safety signals of concern observed to date**
- ✓ **Anti-HER2-specific antibody responses in all evaluable patients**
- ✓ **Durable antibody titers**

Encouraging immune activation consistent with active immunotherapy


¹ Patients are receiving heterogeneous background therapies (including kinase inhibitors, hormone therapy, and ADCs), contributing to variability; expanded enrolment will improve interpretability.

² As of 24 March 2026

ES2B-C001: Large Market Opportunity

HER2-targeted therapies represent a major oncology market

Proven Commercial Value of HER2 Drugs (2024, EUR billion) ¹



Global market: HER2-expressing breast cancer therapies exceeded **€17B globally in 2024¹**



Estimated addressable opportunity: **> €5B**

Key opportunity:


- New immunotherapy approaches & other HER2 cancers
- Potential use in combination with existing therapies

¹ Source: Company annual reports and public disclosures (Roche, AstraZeneca, Daiichi Sankyo, Puma Biotechnology), industry market estimates for trastuzumab biosimilars. Includes global 2024 revenues from HER2-targeted therapies (mAbs, ADCs, TKIs, biosimilars). Figures represent reported sales and market estimates; excludes non-HER2 breast cancer therapies and may not capture all regional products.

³ Research and Markets. Adalimumab, Infliximab, Etanercept, Trastuzumab Biosimilars Global Market Report 2024 [Internet]. Dublin: Research and Markets; 2024 [cited 2025 Mar 10]. Available from: <https://www.researchandmarkets.com/reports/6044811/adalimumab-infliximab-etanercept-trastuzumab>

ES2B-C001: Development Strategy

Goal: Out-license when Phase II delivers proof – or earlier if signals are strong




Industry precedent:

- Multiple multi-billion dollar partnership deals in HER2 oncology

Pipeline Overview

Multiple shots on goal across cancer and infectious diseases, powered by our ExpreS2 platform, and AdaptVac's VLP in some cases



¹ ES2B-C001 is fully sponsored by ExpreS2ion


² Vaccine project funded by non-diluting funding. For RH5.1 and R78C, ExpreS2ion and Serum Institute of India have entered a licensing agreement in Q4 '25 regarding development and commercialisation. For RH5.2-VLP, University of Oxford applies their own VLP technology.

³ ABNCoV2 was fully sponsored by Bavarian Nordic ("BN"), who proved the platform's viability in more than 4,000 people in Phase II and Phase III. BN decided in Q3 '23 to halt the program for commercial reasons.

Rights Issue

Funding to complete Phase I and reach value inflection


Cash Development Last 18 Months



Important Cash In-flow in 2026

Rights Issue of ~53mSEK

- ~60% secured
- Subscription period: Apr. 16 – 30, '26
- Terms: 1 share = 1 unit (1 new share + TO13 warrant)
- Price: 70% of the average price during Mar. 24 – Apr. 6, '26



TO 13 warrant subscription

- Subscription: Sep. 7 – 21, '26
- Terms: 1 warrant = 1 new share
- Price: 70% of the average price during Aug. 20 – Sep. 2, '26

Use of Proceeds

1. Advance ES2B-C001 (55%)
2. Strengthen shared R&D and manufacturing capabilities (20%)
3. Grow the contract research business (20%)
4. Co-finance grant projects (5%)

Leadership: Fully capable of executing to Phase II

Extensive Clinical Development, Oncology & Licensing Experience

Executive Management



Bent U. Frandsen, MSc
Chief Executive Officer
28+ year biotech leadership



Keith Alexander, MSc
Chief Financial Officer
24+ years in financial management



Dr. Max M. Soegaard, PhD
Chief Scientific Officer
24+ years research experience

+ 15 FTE colleagues (6 PhDs)

+ consulting executives

200+ years of clinical development and pharma/biotech business experience

Board of Directors



Dr. Martin Roland Jensen, PhD,
Co-Founder and Chairman
Co-Founder of Expres2ion Biotechnologies



Jakob Knudsen, LL.M., MBA,
Board Member
CEO of Virogates, Board Member of Ingeniørsystem and PV Fonden



Dr. Karin Garre, MD,
Board Member
Chair of Bioneer and Board Member of Cervello





Sara Sande, MSc,
Board Member
Investment Partner at EIFO, Board Member of Agreena, Monta and Biosyntia

Proven experience from: H. Lundbeck | Novo Nordisk | Sanofi | GSK | Janssen | Novartis

Upcoming Catalysts

Multiple value-driving readouts anticipated over the next 12-18 months

 ES2B-C001 (Breast cancer)	Phase Ia dose escalation Interim safety/immunogenicity readouts							Phase Ib expansion RP2D + safety/immunogenicity Preliminary efficacy signals				Outlicensing / Phase II		
	CMC manufacturing start								GMP batch release for Tox/IND- enabling studies		Tox /IND- enablement			
 Malaria (Oxford/SIPL)	Selected clinical readouts												Additional licensing (TBD)	
	INDIGO programs concludes (scheduled)												Further development (TBD)	
1/26 2/26 3/26 4/26 5/26 6/26 7/26 8/26 9/26 10/26 11/26 12/26													Upcoming	

Timing and milestones are forward-looking and subject to change based on clinical progress, regulatory interactions, manufacturing outcomes, funding availability, and collaboration partner decisions.

Why Invest Now

- 1 First-in-class HER2 immunotherapy
- 2 Encouraging immune responses in Phase I
- 3 Validated protein platform (Phase III track record)
- 4 €17B HER2 oncology market
- 5 Clear Phase I/II licensing strategy
- 6 Multiple catalysts over next 12-18 months

Q&A

NASDAQ FN:
EXPRS2

Innovative
immunotherapies
for a healthier
world

investor@
expres2ionbio.com

[https://investor.
expres2ionbio.com](https://investor.expres2ionbio.com)

Disclaimer

This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the "Company"). Neither shall the presentation or any part of it, nor the fact of its distribution or communication, form the basis of, or be relied on in connection with, any contract, commitment or investment decision in relation thereto.

This presentation contains forward-looking statements, which are subject to risks and uncertainties because they relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-looking statements give Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Company or the industry in which it operates, to be materially different than any future results, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements referred to above speak only as at the date of the presentation. Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect future events, circumstances, anticipated events, new information or otherwise except as required by law or by any appropriate regulatory authority.

The information included in this presentation may be subject to updating, completion, revision and amendment and such information may change materially. No person, including Company and its advisors, is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. Neither Company nor any of its owners, affiliates, advisors or representatives (jointly the "Disclosers") make any guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this presentation, and no reliance should be placed on such information. None of the Disclosers accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith.

By attending this presentation or by accepting any copy of this document, you agree to be bound by the foregoing limitations.